Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12...2627282930313233343536...6263»
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, Monotherapy:  Sustained viral suppression with dolutegravir monotherapy in a treatment-experienced adult with perinatally acquired HIV. (Pubmed Central) -  Nov 5, 2021   
    The patient has successfully maintained prolonged viral suppression for over 3 years with intermittent blips secondary only to intermittent medical issues. This case is unique in describing a highly treatment-experienced young adult with perinatal HIV infection who has been virally suppressed on dolutegravir monotherapy for a prolonged follow-up of 156 weeks.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Preclinical, Journal:  No developmental toxicity observed with dolutegravir in rat whole embryo culture. (Pubmed Central) -  Nov 4, 2021   
    This case is unique in describing a highly treatment-experienced young adult with perinatal HIV infection who has been virally suppressed on dolutegravir monotherapy for a prolonged follow-up of 156 weeks. DTG at the maximum human recommended dose administered to rats in a whole embryo culture assay did not produce any abnormal effects, while the positive control Valproic Acid produced abnormal effects, including neural tube defects.
  • ||||||||||  zidovudine / Generic mfg.
    Journal:  Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa. (Pubmed Central) -  Oct 29, 2021   
    Introduction of tenofovir (TDF) plus lamivudine (3TC) and dolutegravir (DTG) in first- and second-line HIV treatment regimens in South Africa warrants characterization of acquired HIV-1 drug resistance (ADR) mutations that could impact DTG-based antiretroviral therapy (ART)...Most participants (82%) with first-line viraemia maintained susceptibility to Zidovudine (AZT), and the majority of them had lost susceptibility to TDF (71%) and 3TC (84%)...As most patients with first-line viraemia had at least low-level resistance to TDF and 3TC, identifying viraemia before switch to TDF + 3TC + DTG is important to avoid DTG functional monotherapy. These findings highlight a need for close monitoring of outcomes on new standardized treatment regimens.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Clinical, Journal:  Tocilizumab in HIV patient with severe COVID-19: case report. (Pubmed Central) -  Oct 29, 2021   
    The patient had several risk factors, such as male gender, age  >  70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient's recovery since the drug increased his immune response, which is deficient, due to HIV infection.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal:  Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa. (Pubmed Central) -  Oct 27, 2021   
    Dolutegravir based regimens offer the safest DDI profile for concurrent use with anticancer drugs. However, there are substantial gaps in our knowledge, and this study serves to highlight the need for additional research to better define these interactions and their effect on drug exposure, as attention to these DDIs is a relatively simple intervention that could lead to optimizing disease treatment.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    Clinical, Journal:  Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV? (Pubmed Central) -  Oct 27, 2021   
    The most recent study, QUATUOR, found that a 4-day on, 3-day off pattern was non-inferior to the continuous pattern (7 days on). Better-quality studies with long-term follow-up (96 weeks or more) are needed to determine the validity of intermittent treatment and the optimal regimens and monitoring to be used in the management of viro-logically suppressed patients living with HIV.
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, HEOR:  Dolutegravir in Mexico for special populations: A cost analysis perspective. (Pubmed Central) -  Oct 27, 2021   
    They include raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and bictegravir (BIC)...This is partially due to the increase in the pre-treatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI), mainly efavirenz (EFV)...Tuberculosis is a common coinfection in Mexico that requires rifampin-based anti-tuberculosis therapy, which requires increasing DTG to double dosing (50 mg BID). In Mexico, DTG-based regimens are likely to be cost-effective in many scenarios, given its acquisition costs and the particularities of the HIV population and associated clinical conditions, including a relatively high proportion of the following: i) new HIV diagnoses presenting at acquired immunodeficiency syndrome (AIDS) stage; ii) high rate of tuberculosis coinfection; iii) frequent first-line NNRTI treatment failures; and iv) relatively high proportion of infected children and adolescents.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    PK/PD data, Journal:  Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions. (Pubmed Central) -  Oct 22, 2021   
    This study examined how the pharmacokinetics of DTG are affected by co-administration with Al(OH), LaCO, and the polycation polymers bixalomer (Bxl) and sevelamer (Svl)...These comparisons also revealed a considerable reduction in the maximum concentration, suggesting that the interactions of these agents with DTG in the intestinal tract inhibit absorption of DTG. The above results demonstrate that Al(OH), LaCO, Bxl, and Svl affect the pharmacokinetics of DTG and indicate the need for caution when combining any of the above preparations with DTG.
  • ||||||||||  Pifeltro (doravirine) / Merck (MSD)
    Journal:  Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa. (Pubmed Central) -  Oct 20, 2021   
    Although doravirine is approved as initial therapy in patients who are ART-naïve, it is currently recommended to obtain a genotype prior to the initiation of ART. Clinical studies are needed to ascertain whether predicted resistance profiles in ART naïve and NNRTI-treated patients translate into poor clinical outcomes, especially in settings where genotypic resistance testing is not available.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal:  A reflective process led by a family physician to develop a renal-protection surveillance tool for HIV patients newly started on dolutegravir. (Pubmed Central) -  Oct 20, 2021   
    A group of Vanguard Community Health Centre doctors embarked on a Health System's Improvement (HSI) project with the aim of reducing harm to renal function in patients who were either commenced on or switched to a dolutegravir (DTG)-based antiretroviral therapy (ART) regimen since 2019, when the usual monitoring and evaluation of ART-regimen switches were disrupted by the coronavirus disease 2019 (COVID-19) pandemic. This intended harm-reduction exercise, involving a reflective process that was facilitated by the family physician, led to the development of a Vanguard Renal Protection Surveillance tool, which is now used at Vanguard to detect and prevent renal decline.
  • ||||||||||  Trial completion date, Trial primary completion date:  BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA) (clinicaltrials.gov) -  Oct 20, 2021   
    P1/2,  N=77, Recruiting, 
    This intended harm-reduction exercise, involving a reflective process that was facilitated by the family physician, led to the development of a Vanguard Renal Protection Surveillance tool, which is now used at Vanguard to detect and prevent renal decline. Trial completion date: Sep 2021 --> Mar 2022 | Trial primary completion date: Aug 2021 --> Mar 2022
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    [VIRTUAL] Rapidly Progressive Glomerulonephritis due to Crescentic IgA Nephropathy in the Setting of HIV () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2632;    
    A few prior case reports describe stable IgA nephropathy in individuals with HIV, suggesting that there may be some unifying pathogenesis. This case highlights the need for investigation of this potential mechanism, which may help determine the optimal therapy for IgA nephropathy and IgA-induced RPGN in the setting of HIV.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Observational data, Journal:  Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. (Pubmed Central) -  Oct 15, 2021   
    In this prospective observational study, we found high DTG durability and a low rate of virological failures. Dual therapies seemed protective toward AEs and might be considered, when feasible, a suitable option to minimize drug interactions and improve tolerability.
  • ||||||||||  bictegravir (GS-9883) / Gilead
    Journal:  Are New Antiretroviral Treatments Increasing the Risk of Weight Gain? (Pubmed Central) -  Oct 13, 2021   
    Evidence with cabotegravir, the newest integrase inhibitor, is limited...Evidence suggests that the nucleoside reverse transcriptase backbone has additional effects on weight gain, with tenofovir alafenamide potentially enhancing the weight gain effect...New thresholds for weight gain should be established as guidance for clinicians to stop treatment where weight gain is excessive. Novel treatments such as doravirine could offer a suitable therapy alternative, with current evidence showing efficacy with limited effect on weight gain.
  • ||||||||||  rifampicin / Generic mfg.
    Enrollment open, Trial initiation date:  ORCHID: Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB (clinicaltrials.gov) -  Oct 13, 2021   
    P4,  N=20, Recruiting, 
    Novel treatments such as doravirine could offer a suitable therapy alternative, with current evidence showing efficacy with limited effect on weight gain. Not yet recruiting --> Recruiting | Initiation date: Mar 2021 --> Aug 2021
  • ||||||||||  bictegravir (GS-9883) / Gilead
    [VIRTUAL] Evaluating Weight Gain in Treatment-naïve, HIV-infected Patients Started on Antiretroviral Therapy () -  Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1801;    
    The non-INSTI-based regimens were darunavir (DRV) or rilpivirine (RPV)-based...Of the patients initiated on INSTI-based regimens, 73.5% were on elvitegravir (EVG),16.7% on dolutegravir, 8.8% on bictegravir, and 0.98% on raltegravir... When comparing INSTI-based to DRV or RPV-based regimens, there was no significant increase in average weight at 6 and 18 months.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
    Trial completion date, Trial primary completion date, Combination therapy:  DYNAMIC: A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (clinicaltrials.gov) -  Oct 5, 2021   
    P2b,  N=80, Recruiting, 
    Improving urgent access to these critical medications in rural communities is an opportunity for HIV prevention. Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Nov 2022 | Trial completion date: Jan 2023 --> Jun 2023
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, GSK3640254 / ViiV Healthcare
    Trial completion date, Trial primary completion date, Combination therapy:  DOMINO: A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults (clinicaltrials.gov) -  Oct 4, 2021   
    P2b,  N=150, Recruiting, 
    Trial completion date: Jan 2023 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Nov 2022 | Trial completion date: Jan 2023 --> Jun 2023 Trial completion date: Aug 2028 --> Dec 2028 | Trial primary completion date: Jun 2022 --> Oct 2022
  • ||||||||||  Prezcobix (darunavir/cobicistat) / Gilead, J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  BK polyomavirus associated progressive multifocal leukoencephalopathy in a person living with HIV. (Pubmed Central) -  Oct 1, 2021   
    There have been 5 case reports in the literature of BK virus as the cause of PML. Testing for BK virus should be considered in patients presenting with signs and symptoms of PML and encephalitis particularly when no other cause is found.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Clinical, Journal, Adverse events:  Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. (Pubmed Central) -  Oct 1, 2021   
    Symptoms such as anxiety, insomnia or depression can be DTG AEs more frequently than expected. Being identified by primary care and emergency physicians could avoid the unnecessary prescription of other medications.